Search Legislation

The Medicines for Human Use (Marketing Authorisation Etc.) Amendment Regulations 1998

What Version

 Help about what version
  • Latest available (Revised)
  • Original (As made)

Opening Options

 Help about opening options

Status:

This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

Explanatory Note

(This note is not part of the Regulations)

These Regulations amend the Medicines for Human Use (Marketing Authorisation Etc.) Regulations 1994 (“the principal Regulations”) to make further provision implementing Council Directive 92/27/EEC (O.J. No. L113 of 30.4.1992) (“the Directive”) by requring necessary special warnings to be included on the packaging of relevant medicinal products containing paracetamol, and in package leaflets accompanying those products.

The new paragraph 5(1)(f) of Schedule 5 to the principal Regulations specifies the new warnings which must appear on the packaging of paracetamol products for adult use. The new paragraph 5(1)(g) specifies similar warnings in respect of products for paediatric use. Paragraph 5(2) of Schedule 5 to the principal Regulations is amended so that the required label warnigns must appear prominently and in a rectangle (regulation 3).

Paragraph 1 of the new Schedule 5A to the principal Regulations specifies the new warning which must appear in any package leaflet included in accordance with the Directive in the packaging of a paracetamol product for adult use, and paragraph 2 of the Schedule specifies the warning which must appear in any package leaflet included in accordance with the Directive in the packaging of a paracetamol product for paediatric use (regulation 4).

Consequential amendments are made to paragraphs 11 and 12 of Schedule 3 to the principal Regulations, making breaches of the new requirements offences (regulation 5).

A Regulatory Appraisal in relation to these Regulations has been placed in the libraries of both Houses of Parliament, and copies can be obtained from the Medicines Control Agency, Room 1207, Market Towers, 1 Nine Elms Lane, London SW8 5NQ.

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made):The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enactedversion that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources